NuVasive Beheer

Beheer criteriumcontroles 3/4

De CEO NuVasive is Chris Barry, benoemd in Nov2018, heeft een ambtstermijn van 4.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.08M, bestaande uit 11.1% salaris en 88.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.14% van de aandelen van het bedrijf, ter waarde $ 2.90M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.7 jaar en 5.6 jaar.

Belangrijke informatie

Chris Barry

Algemeen directeur

US$8.1m

Totale compensatie

Percentage CEO-salaris	11.1%
Dienstverband CEO	4.8yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	3.7yrs
Gemiddelde ambtstermijn bestuur	5.6yrs

Recente managementupdates

Recent updates

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

Apr 18

What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?

Jan 24

NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price

Dec 31

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

Dec 05

These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well

Nov 13

NuVasive Non-GAAP EPS of $0.47 misses by $0.09, revenue of $310.5M beats by $4.12M

Aug 03

NuVasive: Industry Tailwinds More Than Fairly Priced

Jun 13

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Jun 01

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

May 11

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

Apr 20

At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?

Mar 30

NuVasive's Turnaround Story Needs A Boost From Better Results

Mar 01

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Dec 28

Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?

Dec 02

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

Nov 11

NuVasive, Inc. (NASDAQ:NUVA) Shares Could Be 32% Below Their Intrinsic Value Estimate

Oct 21

Be Wary Of NuVasive (NASDAQ:NUVA) And Its Returns On Capital

Sep 29

At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?

Aug 18

NuVasive Still Getting No Love With COVID-19 And Competitive Worries

Aug 12

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

Jul 27

Are Investors Undervaluing NuVasive, Inc. (NASDAQ:NUVA) By 21%?

Jun 17

Some Investors May Be Worried About NuVasive's (NASDAQ:NUVA) Returns On Capital

May 30

Why We Think NuVasive, Inc.'s (NASDAQ:NUVA) CEO Compensation Is Not Excessive At All

May 12

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

Mar 30

Is Now The Time To Look At Buying NuVasive, Inc. (NASDAQ:NUVA)?

Mar 09

Need To Know: NuVasive, Inc. (NASDAQ:NUVA) Insiders Have Been Buying Shares

Feb 16

A Look At The Fair Value Of NuVasive, Inc. (NASDAQ:NUVA)

Jan 26

NuVasive stock gains on study results of its X360 surgery approach

Jan 06

What Type Of Returns Would NuVasive's(NASDAQ:NUVA) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Jan 05

Analyse CEO-vergoeding

Hoe is Chris Barry's beloning veranderd ten opzichte van NuVasive's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2023	n/a	n/a	US$28m
Mar 31 2023	n/a	n/a	US$20m
Dec 31 2022	US$8m	US$897k	US$40m
Sep 30 2022	n/a	n/a	-US$20m
Jun 30 2022	n/a	n/a	-US$40m
Mar 31 2022	n/a	n/a	-US$37m
Dec 31 2021	US$8m	US$875k	-US$64m
Sep 30 2021	n/a	n/a	-US$26m
Jun 30 2021	n/a	n/a	US$2m
Mar 31 2021	n/a	n/a	-US$50m
Dec 31 2020	US$5m	US$735k	-US$37m
Sep 30 2020	n/a	n/a	-US$9m
Jun 30 2020	n/a	n/a	-US$4m
Mar 31 2020	n/a	n/a	US$61m
Dec 31 2019	US$5m	US$800k	US$65m
Sep 30 2019	n/a	n/a	US$48m
Jun 30 2019	n/a	n/a	US$52m
Mar 31 2019	n/a	n/a	US$49m
Dec 31 2018	US$5m	US$92k	US$12m

Compensatie versus markt: De totale vergoeding ($USD 8.08M ) Chris } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.34M ).

Compensatie versus inkomsten: De vergoeding van Chris is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Chris Barry (50 yo)

4.8yrs

Tenure

US$8,077,095

Compensatie

Mr. J. Christopher Barry, also known as Chris, serves as Chief Executive Officer and Director of NuVasive, Inc., since November 5, 2018. Mr. Barry served commercial and leadership roles at Covidien. He has...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
J. Barry	CEO & Director	4.8yrs	US$8.08m	0.14% $ 2.9m
Matthew Harbaugh	Principal Accounting Officer	3.7yrs	US$2.97m	0.020% $ 418.2k
Dale Wolf	Senior Vice President of Global Operations	3.7yrs	US$1.48m	0.017% $ 355.5k
Nathaniel Sisitsky	Senior VP	5.3yrs	US$1.54m	0.042% $ 869.2k
Michael Farrington	Senior Vice President of People & Culture	less than a year	US$1.03m	0.0059% $ 123.8k
Ryan Donahoe	Senior VP & Chief Technology Officer	2yrs	geen gegevens	geen gegevens
Juliet Cunningham	Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Sean Freeman	Senior Vice President of Strategy & Corporate Development	3.8yrs	geen gegevens	geen gegevens
Lisa Pecora	Vice President & Head of Global Commercial Finance	5.3yrs	geen gegevens	geen gegevens
Aviva McPherron	Senior Vice President of Information Technology	1.7yrs	geen gegevens	geen gegevens
Tristan Ribar	Vice President	5.3yrs	geen gegevens	geen gegevens

3.7yrs

Gemiddelde duur

48yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NUVA wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
J. Barry	CEO & Director	4.8yrs	US$8.08m	0.14% $ 2.9m
John DeFord	Independent Director	5.6yrs	US$260.01k	0% $ 0
Robert Friel	Independent Director	7.6yrs	US$260.01k	0% $ 0
Vickie Capps	Independent Director	8.3yrs	US$280.01k	0.0038% $ 79.4k
R. Huennekens	Independent Director	4.9yrs	US$260.01k	0.0026% $ 54.0k
Daniel Wolterman	Independent Chair	8.2yrs	US$405.01k	0% $ 0
Leslie Norwalk	Independent Director	9.3yrs	US$270.01k	0.0059% $ 123.0k
Siddhartha Kadia	Independent Director	2.6yrs	US$260.01k	0.0071% $ 148.7k
Amy Raimundo	Independent Director	2.1yrs	US$260.01k	0% $ 0

5.6yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NUVA wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.6 jaar).

NuVasive Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

NuVasive, Inc. Announces Resignation of Marc Rosenbaum as Vice President, Corporate Controller and Chief Accounting Officer

NuVasive, Inc., Annual General Meeting, Jun 09, 2023

CEO & Director exercised options and sold US$491k worth of stock

NuVasive, Inc. Announces Departure of Massimo Calafiore as Executive Vice President and Chief Commercial Officer, Effective August 31, 2022

NuVasive, Inc. Announces Management Changes

NuVasive, Inc., Annual General Meeting, May 11, 2022

Recent updates

NuVasive Files Form 15

NuVasive, Inc.(NasdaqGS:NUVA) dropped from NASDAQ Composite Index

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Consensus EPS estimates fall by 19%

New minor risk - Earnings quality

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

NuVasive, Inc. Provides Sales Guidance for the Full Year 2023

NuVasive, Inc. to Report Q2, 2023 Results on Aug 02, 2023

NuVasive, Inc. Announces Resignation of Marc Rosenbaum as Vice President, Corporate Controller and Chief Accounting Officer

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

NuVasive, Inc. Provides Sales Guidance for the Year 2023

NuVasive, Inc., Annual General Meeting, Jun 09, 2023

NuVasive, Inc. to Report Q1, 2023 Results on May 10, 2023

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

CEO & Director exercised options and sold US$491k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Globus Medical, Inc. (NYSE:GMED) entered into a definitive agreement to acquire NuVasive, Inc. (NasdaqGS:NUVA) for $3.1 billion.

NuVasive, Inc. to Report Q4, 2022 Results on Feb 22, 2023

What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?

NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

Price target decreased to US$49.25

These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

NuVasive, Inc. Revises Earnings Guidance for the Year 2022

NuVasive, Inc. Launches Tube System and Excavation Micro for Posterior Spine Surgery

NuVasive, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Price target decreased to US$56.00

Nuvasive Launches Reline Cervical for Posterior Cervical Fusion as Part of the C360 Portfolio

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

NuVasive Likely Undervalued, But It's Hard To Find Catalysts

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

NuVasive, Inc. Announces Departure of Massimo Calafiore as Executive Vice President and Chief Commercial Officer, Effective August 31, 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

NuVasive, Inc. Revises Earnings Guidance for the Full Year of 2022

NuVasive Non-GAAP EPS of $0.47 misses by $0.09, revenue of $310.5M beats by $4.12M

NuVasive, Inc. to Report Q2, 2022 Results on Aug 03, 2022

NuVasive: Industry Tailwinds More Than Fairly Priced

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

NuVasive, Inc. Announces Management Changes

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Now 21% undervalued after recent price drop

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

NuVasive, Inc. Revises Earnings Guidance for the Full Year of 2022

NuVasive, Inc. to Report Q1, 2022 Results on May 04, 2022

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

NuVasive, Inc., Annual General Meeting, May 11, 2022

At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?

NuVasive's Turnaround Story Needs A Boost From Better Results

Full year 2021 earnings: EPS exceeds analyst expectations

NuVasive, Inc. Provides Earnings Guidance for the Full Year 2022

NuVasive, Inc. to Report Q4, 2021 Results on Feb 23, 2022

NuVasive, Inc. Appoints Andrew C. Morton as Senior Vice President and Chief Human Resources Officer, Effective February 7, 2022

Nuvasive Receives FDA Clearance for Expanded Indications of Use for Attrax Putty with Thoracolumbar Interbody Portfolio

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Price target decreased to US$66.19

Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?

CEO & Director exercised options and sold US$708k worth of stock

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.12 profit in 3Q 2020)

NuVasive, Inc. (NASDAQ:NUVA) Shares Could Be 32% Below Their Intrinsic Value Estimate

Be Wary Of NuVasive (NASDAQ:NUVA) And Its Returns On Capital

Senior VP & Chief Human Resources Officer Lucas Vitale has left the company

NuVasive, Inc. Simplify Cervical Disc Data Publishes in International Journal of Spine Surgery

Key Executive exercised options and sold US$77k worth of stock

High number of new directors

At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?